Oncotarget Immune Checkpoint Inhibitors May Improve Outcomes in High-Risk Solid Tumors This systematic review and meta-analysis of 13 randomized controlled trials including 9,850 patients shows... read more May 20, 2026
Oncotarget SCD1 Inhibition Strategy Shows Potent Synergy with Regorafenib and Metformin in Tumor Cell Killing Our data demonstrates that UM cells are killed by treatment with aramchol plus regorafenib plus... read more April 21, 2026
Oncotarget CREB5: A Master Regulator of Stem Cell-Like Programs in Prostate Cancer Progression In this study, through both computational and molecular characterization of PC cell lines, we determined... read more April 7, 2026
Oncotarget Predicting Colorectal Cancer Survival: How Machine Learning Combines Clinical and Biological Clues Understanding both the biological and clinical aspects of the patient is essential to uncover the... read more March 25, 2026
Oncotarget Overcoming Aromatase Inhibitor Resistance in Breast Cancer: A New Therapeutic Strategy The estrogen receptor is overexpressed in and promotes 67-80% and 90% of female and male... read more January 13, 2026
Oncotarget Comprehensive Genomic Profiling in Cancer: Insights from Over 10,000 Tumors The OncoExTra® assay (formerly GEM ExTra) is a whole exome, whole transcriptome, tumor-normal genomic profiling... read more December 15, 2025
Oncotarget Repurposing Statins: Exploring Anti-Tumor Effects in Colorectal Cancer Drug repurposing has gained traction as a viable strategy to target dysregulated oncogenic pathways."Colorectal... read more December 3, 2025
Oncotarget New Antibody Removes Tregs to Boost Immune Response Against Cancer Treg play a deleterious role in the tumor microenvironment by suppressing anti-tumor effector T cells."... read more November 19, 2025
Oncotarget How Low Oxygen Shields Prostate Cancer from Ferroptosis Therapies Preclinical and clinical studies indicate that ferroptosis suppresses tumor growth, and dysregulation of ferroptosis promotes... read more November 6, 2025
Oncotarget Genetic Study Identifies Potential Diagnostic Marker for Rare Blood Cancer BPDCN Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poorly characterized molecular... read more October 22, 2025